Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
The Lancet Regional Health. Europe|January 1, 2024
Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in SwitzerlandPaul Thoueille, Susana Alves Saldanha, Fabian Schaller, et al.AIDS (London, England)|December 11, 2023
Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomesAmanda Mocroft, Annegret Pelchen-Matthews, Jennifer Hoy, et al.HIV Medicine|March 2, 2022
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortiumDathan M Byonanebye, Mark N Polizzotto, Bastian Neesgaard, et al.BMJ Open|November 22, 2024
Booster-free anti-retroviral therapy for persons living with HIV and multidrug resistance (B-Free): protocol for a multicentre, multistage, randomised, controlled, non-inferiority trialMarie Ballif, Dominique Braun, Alexandra Calmy, et al.Journal of Clinical Epidemiology|September 14, 2025
Implementing a randomization consent to enable Trials within Cohorts in the Swiss HIV Cohort Study - A mixed-methods studyElias R Zehnder, Christof Manuel Schönenberger, Julia Hüllstrung, et al.Tobacco Induced Diseases|May 28, 2026
Acceptance and preferences for different nicotine substitute products to reduce tobacco smoking in people living with HIV: Results from an internal pilot study of a randomized trialChristof M Schönenberger, Stephanie Campos Ochoa, Benjamin Speich, et al.AIDS (London, England)|March 25, 2026
Risk of type 2 diabetes mellitus after treatment with direct-acting antivirals for Hepatitis C virus in people with HIVMathieu Chalouni, Jessie Torgersen, Christopher T Rentsch, et al.AIDS (London, England)|February 19, 2025
Time to direct-acting antiviral initiation and liver-related events in people with HIV and hepatitis C virusMathieu Chalouni, Daniela K Van Santen, Juan Berenguer, et al.HIV Medicine|September 29, 2023
Incidence of sexually transmitted infections and association with behavioural factors: Time-to-event analysis of a large pre-exposure prophylaxis (PrEP) cohortFrédérique Hovaguimian, Roger D Kouyos, Katharina Kusejko, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 18, 2025
Risk of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C virus infection in people with HIVDaniela K van Santen, Mathieu Chalouni, Juan Berenguer, et al.Pageof 5